Nektar Therapeutics NKTR Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's operating lease liabilities?
- Nektar Therapeutics (NKTR) reported operating lease liabilities of $60.63M in Q1 2026.
- How has Nektar Therapeutics's operating lease liabilities changed year-over-year?
- Nektar Therapeutics's operating lease liabilities decreased by 22.8% year-over-year, from $78.5M to $60.63M.
- What is the long-term trend for Nektar Therapeutics's operating lease liabilities?
- Over 5 years (2020 to 2025), Nektar Therapeutics's operating lease liabilities has grown at a -13.7% compound annual growth rate (CAGR), from $136.37M to $65.26M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.